ImpediMed Limited (IPD.XA)
Cboe AU · AUD
A$0.004 (+0.00%) as of
Key statistics
- EPS (TTM)
- -0.0130
- 52-week range
- 0.0035 – 0.0500
- Beta
- 1.07
- Revenue (TTM)
- 14.61M
- Profit margin
- -170.44%
- Volume
- 7.72M
About ImpediMed Limited
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Prevention Program; and BodyComp Analysis for survivorship health. The company specializes in cancer survivorship, heart health management, medical weight management, wellness, and research. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California.
- Headquarters
- Carlsbad, CA, United States
- Employees
- 66
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.